Cervarix® [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] – Product discontinuation
October 18, 2016 – GlaxoSmithKline announced the discontinuation of Cervarix [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] in the U.S. due to very low market demand.
Download PDF
